English | Español
English | Español
  • Insurance
  • Marketing
  • Pharmaceuticals
  • Technology/Innovation
  • Regulatory
  • Community

Janssen

Press release submission | Dec 29, 2021

Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Press release submission | Dec 22, 2021

FDA Approves Two New Indications for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients

Press release submission | Aug 19, 2021

Janssen Presents Phase 1 Results for RYBREVANT™ (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations

Press release submission | May 21, 2021

RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Press release submission | Jan 16, 2019

JANSSEN: Announces European Commission approval of ERLEADA®(apalutamide) for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease

Press release submission | Dec 6, 2018

JANSSEN: DARZALEX® (daratumumab) Combination Regimens Show Positive Results for Newly Diagnosed and Relapsed Patients with Multiple Myeloma

Trending

+ Pharmaceuticals
Patient Daily | Jul 22, 2025

Deputy VP of Public Affairs of PhRMA: 'It's time for Congress to fix the 340B Drug Pricing Program'

Patient Daily | Jul 24, 2025

Long School of Medicine is largest physician trainer in South Texas

Patient Daily | Jul 25, 2025

Healthcare CEO on 340B reform: ‘It’s the abuse by very large, very profitable, tax-exempt institutions that I think needs to change'

Patient Daily | Jul 25, 2025

Balloon sinuplasty marks 20 years since FDA approval



Community
Insurance
Marketing
Pharmaceuticals
Regulatory
Technology/Innovation
About
Contact
© 2025 Patient Daily